Tests a radioactive drug and a scan agent in adults with advanced solid tumors
Tests a radioactive drug and a scan agent in adults with advanced cancers.
Plain-language title generated from the registry record
Registry title: A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
Key facts
- Where
- Copenhagen Oe and Odense C, DenmarkSee the 2 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumours that cannot be removed by surgery or have spread. It tests the safety and early activity of [177Lu]Lu-DFC413 and the imaging agent [68Ga]Ga-NNS309.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Locally advanced and unresectable, or metastatic. Cancer types: soft tissue sarcoma (not GIST or Kaposi sarcoma), pancreatic ductal adenocarcinoma, non-small cell lung cancer, colorectal cancer, triple negative breast cancer, or HR+/HER2- ductal or lobular breast cancer.
Main reasons for not taking part
- Healthy volunteers cannot join.
- People with GIST or Kaposi sarcoma cannot join.
Read by machine on 9 November 2026.
Where in Denmark
- RigshospitaletCopenhagen Oe, DenmarkTaking people
- Odense University HospitalOdense C, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- Novartis Pharma AG
- Trial code
- EU 2025-521702-18-00
- Record updated
- 15 September 2026